Roche swallows US breast cancer drug firm
Staff reporter - [email protected]
Published: 2 Jul, 2014 CET.
Updated: Wed 2 Jul 2014 12:27 CET
Swiss pharmaceutical group Roche said on Wednesday that it was buying Seragon Pharmaceuticals, a US biotechnology firm specializing in a new way to fight breast cancer, in a deal worth up to $1.7 billion.
Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, the Basel-based company said in a statement.
Roche said its Genentech subsidiary would be acquiring Seragon, putting $725 million in cash upfront and adding up to another $1 billion if "certain predetermined milestones" are met.
The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.
Comments
See Also
Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, the Basel-based company said in a statement.
Roche said its Genentech subsidiary would be acquiring Seragon, putting $725 million in cash upfront and adding up to another $1 billion if "certain predetermined milestones" are met.
The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.